Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New proton beam device tested for safer cancer treatment

NCT ID NCT07152353

Disease control Sponsor: Ion Beam Applications Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing a new proton beam therapy device called PROTEUS® PLUS for treating solid tumors in adults. 47 participants will receive radiation from this machine to see if it is safe and effective at controlling tumors. The goal is to gather data for product registration and potentially offer a more precise treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proton beam therapy (PROTEUS® PLUS device)
What this could lead to
If successful, this could provide a safer, more precise radiation option for treating various solid tumors, potentially reducing side effects compared to standard radiation.
What could go wrong
This is an early-stage device trial with only 47 participants, so results may not apply to all patients. Proton therapy is not new, and this specific system may not prove safer or more effective than existing options. Side effects from radiation, including toxicity, are still possible.
Why investors are watching

Ion Beam Applications, a small publicly traded company, is running a 47-patient trial of its PROTEUS PLUS proton therapy system in Sichuan, China. The trial tests whether the device safely and effectively delivers radiation therapy to oncology patients, and the results will support a product registration application. For a company of this size, this readout matters because approval could open a new market for its medical device.

If it works: A positive result could support regulatory approval of the PROTEUS PLUS system in China, potentially allowing the company to sell the device there. That could create a new revenue stream for a small company.

If it fails: The trial could fail to show the device is safe or effective, or regulators could delay or reject the registration application. Trials fail often, and a negative outcome would likely hurt the company's prospects in this market.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (main): * Clinically diagnosed with benign/malignant intracranial tumor and malignant solid tumor of head and neck, chest, abdomen, spine, pelvic cavity and limbs * At least 1 lesion of the tumor to be treated is measurable according to RECIST criteria * Expected survival time of more than 6 months * ECOG performance status of 0 to 2 * Negative pregnancy test (HCG) results within 7 days prior to the first treatment for females of childbearing potential Exclusion Criteria (main): * Contraindications to radiation therapy * Presence of other uncontrolled tumors other than the tumor to be treated * Implants and devices in the treatment area * Re-irradiation * Other conditions that are not suitable for inclusion, as judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor, adult

Contacts and locations

Locations

  • Sichuan Cancer Hospital & Institute

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.